Oestrogen and progesterone receptor status of individual foci in multifocal invasive ductal breast cancer

Acta Oncologica

Volumn 46, Issue 2, 2007, Pages 204-207

  Garimella, V ^a,b   Long, E D ^c   O'Kane, S L ^a,b   Drew, P J ^a,b   Cawkwell, L ^a,b,d  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

^c HULL ROYAL INFIRMARY   (United Kingdom)

^d CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASTECTOMY; MULTIPLE CANCER; PRIORITY JOURNAL; SCORING SYSTEM; STAINING;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 33847041952     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860600897884     Document Type: Article

References (11)

1. King WJ, Greene GL. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature 1984;307:745-7.
2. Regan MM, Gelber RD. Predicting response to systemic treatments: Learning from the past to plan for the future. Breast 2005;14:582-93.
3. Andea AA, Bouwman D, Wallis T, Visscher DW. Correlation of tumor volume and surface area with lymph node status in patients with multifocal/multicentric breast carcinoma. Cancer 2004;100:20-7.
4. Coombs NJ, Boyages J. Multifocal and multicentric breast cancer: Does each focus matter? J Clin Oncol 2005;23:7497-502.
5. Poulsen HS, Jensen J, Hermansen C. Human breast cancer: Heterogeneity of estrogen binding sites. Cancer 1981;48:1791-3.
6. Panahy C, Puddefoot JR, Anderson E, Vinson GP, Berry CL, Turner MJ, et al. Oestrogen and progesterone receptor distribution in the cancerous breast. Br J Cancer 1987;55:459-62.
7. Cawkwell L, Gray S, Murgatroyd H, Sutherland F, Haine L, Longfellow M, et al. Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut 1999;45:409-15.
8. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
9. Coradini D, Oriana S, Mariani L, Miceli R, Bresciani G, Marubini E, et al. Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour? Eur J Cancer 1998;34:825-30.
10. Tse GM, Kung FY, Chan AB, Law BK, Chang AR, Lo KW. Clonal analysis of bilateral mammary carcinomas by clinical evaluation and partial allelotyping. Am J Clin Pathol 2003;120:168-74.
11. Smeds J,Warngerg F, Norberg T, Nordgren H, Holmberg L, Bergh J. Ductal carcinoma in situ of the breast with different histopathological grades and corresponding new breast tumour events: Analysis of loss of heterozygosity. Acta Oncol 2005;44:41-9.